Please login to the form below
Kyntheum
This page shows the latest Kyntheum news and features for those working in and with pharma, biotech and healthcare.
Leo Pharma to market AstraZeneca’s brodalumab outside Europe
Leo Pharma has had approval for brodalumab in the EU, which it markets under the name Kyntheum, since 2017.
Latest news
-
European Commission backs LEO Pharma’s Kyntheum
Drug has been approved to treat moderate-to-severe plaque psoriasis. European regulators have given the go-ahead for LEO Pharma’s Kyntheum (brodalumab) licensing it to treat moderate-to-severe
-
Payback time nears as Sanofi gets CHMP backing for biosimilar Humalog
Meanwhile among other positive opinions granted by the CHMP was one for Leo Pharma's interleukin-17 inhibitor Kyntheum (brodalumab) - acquired from AstraZeneca - for plaque psoriasis.
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
Latest Intelligence
-
Leo has its eyes on the prize
Its landmark partnership with AstraZeneca and the launch of Kyntheum, the fully-human monoclonal antibody targeting psoriasis, and the phase III hope of tralokinumab for atopic dermatitis are part of an
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Congress is in session – how companies are boosting their impact and engagement
- AstraZeneca announces major expansion of Canadian research footprint
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
PMHub
SEVEN STONES COLLECTIVE
Hello. We are the Total Health creative agency. It’s our collective mix of talent that gets us to truly different...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
